Gene · 6121
Papers3,325
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,325
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Higher throughput assays for understanding the pathogenicity of variants of unknown significance (VUS) in the RPE65 gene. | bioRxiv | 2025 | 39975398 | PubTator, text mining | PubMed |
| Clinical trials to gene therapy development and production in Brazil: a review. | Lancet Reg Health Am | 2025 | 39957799 | PubTator, text mining | PubMed |
| Evaluating ocular health in retinal gene therapies. | Clin Exp Optom | 2025 | 39956654 | PubTator, text mining | PubMed |
| Long-term experience with gene augmentation therapy in patients with inherited retinal disease associated with biallelic mutations in RPE65. | Med Genet | 2025 | 39943983 | PubTator, text mining | PubMed |
| Precise Gene Editing Technologies in Retinal Applications. | Adv Exp Med Biol | 2025 | 39930183 | PubTator, text mining | PubMed |
| Prime Editing Strategy to Install the RPE65 c.1430A>G Dominant Mutation. | Adv Exp Med Biol | 2025 | 39930180 | PubTator, text mining | PubMed |
| Frequency and Pattern of Gene Therapy Clinical Trials for Inherited Retinal Diseases. | Adv Exp Med Biol | 2025 | 39930178 | PubTator, text mining | PubMed |
| Real-world outcomes of Voretigene Neparvovec: a single-centre consecutive case series. | Eye (Lond) | 2025 | 39900645 | PubTator, text mining | PubMed |
| Quantification of Fundus Autofluorescence Features in a Molecularly Characterized Cohort of >3500 Patients with Inherited Retinal Disease from the United Kingdom. | Ophthalmol Sci | 2025 | 39896422 | PubTator, text mining | PubMed |
| Managing Retinitis Pigmentosa: A Literature Review of Current Non-Surgical Approaches. | J Clin Med | 2025 | 39860336 | PubTator, text mining | PubMed |
| A Korean Patient With Leber Congenital Amaurosis and a Homozygous RPE65 Variant Originating From a Paternal Uniparental Isodisomy. | Mol Genet Genomic Med | 2025 | 39835736 | PubTator, text mining | PubMed |
| Insights into the effects of subretinal voretigene neparvovec-rzyl in RPE65-associated Leber congenital amaurosis. | Can J Ophthalmol | 2025 | 39828244 | PubTator, text mining | PubMed |
| Flexible and modular latent transition analysis-A tutorial using R. | PLoS One | 2025 | 39823505 | PubTator, text mining | PubMed |
| "Blindness" is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 cases. | Can J Ophthalmol | 2025 | 39788486 | PubTator, text mining | PubMed |
| Deep Learning-Based SD-OCT Layer Segmentation Quantifies Outer Retina Changes in Patients With Biallelic RPE65 Mutations Undergoing Gene Therapy. | Invest Ophthalmol Vis Sci | 2025 | 39745677 | PubTator, text mining | PubMed |
| Leber congenital amaurosis: A clinical and genetic study from a tertiary eye care center. | Indian J Ophthalmol | 2025 | 39728598 | PubTator, text mining | PubMed |
| Therapeutic potential of adult stem cells-derived mitochondria transfer combined with curcumin administration into ARPE-19 cells in age-related macular degeneration model. | Tissue Cell | 2025 | 39705870 | PubTator, text mining | PubMed |
| 12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy. | Br J Ophthalmol | 2025 | 39578019 | PubTator, text mining | PubMed |
| Immunohistochemical expression of Fibrillin-1 in idiopathic epiretinal membranes. | Graefes Arch Clin Exp Ophthalmol | 2025 | 39466436 | PubTator, text mining | PubMed |
| Deletion of the stress response protein REDD1 prevents sodium iodate-induced RPE damage and photoreceptor loss. | Geroscience | 2025 | 39367169 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6121/papers?page=7